Subscribe To
Shareholder alert: the m&a class action firm continues its investigation of the merger – angn, focs, unvr, csii
NEW YORK, April 12, 2023 (GLOBE NEWSWIRE) — Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the �...
April 12, 2023, 9:20 pm
Shareholder alert: the m&a class action firm continues investigating the merger – angn, cnce, vlon
NEW YORK, Jan. 20, 2023 (GLOBE NEWSWIRE) — Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the �...
January 21, 2023, 1:00 am
angion (angn) down on merger agreement with private biotech
angion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined ...
January 18, 2023, 2:18 pm
angion receives nasdaq notice regarding minimum bid price requirements
UNIONDALE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) — angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceu...
December 22, 2022, 2:50 am
angion biomedica pulls the plug on another kidney disease trial - read why
angion Biomedica Corp (NASDAQ: ANGN) has discontinued the JUNIPER Phase 2 trial of ANG-3070, an oral...
June 30, 2022, 6:11 am
angion (angn) kidney drug misses third study goal in 2021
angion's (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fa...
December 13, 2021, 1:50 pm
angion (angn) kidney drug misses third study goal in 2021
angion's (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fa...
December 13, 2021, 1:50 pm
angion (angn) kidney drug misses third study goal in 2021
angion's (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fa...
December 13, 2021, 1:50 pm